As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...
At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...
Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.
In the 557-patient study, Enhertu reduced the risk of disease progression or death by 50%, whilst improving overall survival by 36% compared to chemotherapy – translating to an extra half year ...
At ESMO, Multiple Enhertu Studies Highlight Challenges of Selecting, Managing Breast Cancer Patients
NEW YORK – The recent expansion of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) as a treatment for low HER2-expressing metastatic breast cancer has upended established testing and ...
BioNTech’s BNT323 and others could potentially threaten Enhertu’s long-term market position. Credit: Nemes Laszlo via Shutterstock. The most common and deadliest malignancy among women is breast ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I September 13, 2024 I Results from the DESTINY-Breast12 phase 3b/4 trial showed that ENHERTU ® (trastuzumab deruxtecan) demonstrated substantial overall and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback